The addition of GIP to chemotherapy/hormone therapy reduces resistance to tamoxifen in the treatment of breast cancer, reduces the risk of endometrial hypertrophy and endometrial cancer and the risk of venous thromboembolism. This evidence concerns the gene GIP and breast carcinoma.